SCHEMBL14930732

SCHEMBL14930732

C=CCOC(=O)CC[C@H](NC(C)=O)C(=O)OCC=C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.46
TSHR P16473 1/20 0.45
KMT2A Q03164 3/20 0.44
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 4/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 2/20 0.36
MEN1 O00255 1/20 0.36
PKM P14618 1/20 0.35
CASP1 P29466 3/20 0.34
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 1/20 0.34
EPHX2 P34913 1/20 0.33
PLA2G2C Q5R387 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
ALOX15 P16050 1/20 0.33
NFKB1 P19838 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12537112 0.87 TDP1 (0.46) L3MBTL1TSHRKMT2APOLBTDP1
SCHEMBL13464450 0.84 TSHR (0.47) L3MBTL1TSHRKMT2APOLBTDP1
SCHEMBL14864546 0.82 FOLH1 (0.53) L3MBTL1TSHRKMT2APOLBSMN1; SMN2
SCHEMBL15278121 0.81 TSHR (0.44) L3MBTL1TSHRKMT2APOLBTDP1
SCHEMBL13515321 0.81 TSHR (0.44) L3MBTL1TSHRKMT2APOLBTDP1
SCHEMBL14930704 0.80 TSHR (0.56) L3MBTL1TSHRKMT2APOLBTDP1
SCHEMBL30948733 0.80 SMN1; SMN2 (0.33) L3MBTL1TSHRKMT2APOLBTDP1
SCHEMBL7119567 0.79 SMN1; SMN2 (0.35) TSHRTDP1SMN1; SMN2ALDH1A1CASP1
SCHEMBL7119570 0.79 SMN1; SMN2 (0.35) TSHRTDP1SMN1; SMN2ALDH1A1CASP1
SCHEMBL8628765 0.79 SMN1; SMN2 (0.52) TSHRTDP1SMN1; SMN2ALDH1A1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130115192-A1 Methods for the Preparation of Targeting Agent Functionalized Diblock Copolymers for Use in Fabrication of Therapeutic Targeted Nanoparticles BIND BIOSCIENCES, INC (US) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130115192-A1 Methods for the Preparation of Targeting Agent Functionalized Diblock Copolymers for Use in Fabrication of Therapeutic Targeted Nanoparticles GNE, PAM, EPHA2 L3MBTL1 1614/4885TSHR 1807/4885KMT2A 2240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.